[go: up one dir, main page]

MX2019012757A - Composicion farmaceutica para administracion oral que comprende enzalutamida. - Google Patents

Composicion farmaceutica para administracion oral que comprende enzalutamida.

Info

Publication number
MX2019012757A
MX2019012757A MX2019012757A MX2019012757A MX2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
enzalutamide
oral administration
orally administrable
including enzalutamide
Prior art date
Application number
MX2019012757A
Other languages
English (en)
Other versions
MX394857B (es
Inventor
Sakai Toshiro
Oba Shinsuke
Kojima Ryo
UMEMOTO Yoshiaki
Yoshida Takatsune
Namiki Sachie
Takagi Akira
Aoki Hajime
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2019012757A publication Critical patent/MX2019012757A/es
Publication of MX394857B publication Critical patent/MX394857B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica para administración oral en donde se mejoran las propiedades de solubilidad y/o disolución de enzalutamida y se mantiene la sobresaturación. También se proporciona una composición farmacéutica para administración oral en donde se mejora la capacidad de absorción oral de enzalutamida. La composición farmacéutica para administración oral comprende enzalutamida y alcohol polivinílico.
MX2019012757A 2017-04-28 2018-04-27 Composicion farmaceutica para administracion oral que comprende enzalutamida. MX394857B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017090300 2017-04-28
PCT/JP2018/017159 WO2018199282A1 (ja) 2017-04-28 2018-04-27 エンザルタミドを含有する経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
MX2019012757A true MX2019012757A (es) 2019-12-16
MX394857B MX394857B (es) 2025-03-24

Family

ID=63920425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012757A MX394857B (es) 2017-04-28 2018-04-27 Composicion farmaceutica para administracion oral que comprende enzalutamida.

Country Status (13)

Country Link
US (1) US12036315B2 (es)
EP (1) EP3616696B1 (es)
JP (1) JP7172997B2 (es)
KR (1) KR102684756B1 (es)
CN (1) CN110573153B (es)
AU (1) AU2018256998B2 (es)
CA (1) CA3060366A1 (es)
ES (1) ES3018265T3 (es)
MX (1) MX394857B (es)
PL (1) PL3616696T3 (es)
PT (1) PT3616696T (es)
RU (1) RU2019138248A (es)
WO (1) WO2018199282A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057701T2 (hu) 2012-09-11 2022-05-28 Medivation Prostate Therapeutics Llc Enzalutamid kiszerelési formái
JP6751491B1 (ja) 2018-12-27 2020-09-02 旭化成株式会社 セルロース粉末、その使用および錠剤
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤
WO2021240206A1 (en) * 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
JP7414668B2 (ja) 2020-08-28 2024-01-16 信越化学工業株式会社 ポリビニルアルコール含有造粒物及び固形製剤
IL302344A (en) * 2020-10-28 2023-06-01 Merck Patent Gmbh Pharmaceutical composition and method for enhancing solubility of poorly soluble active pharmaceutical ingredients
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
KR20250058470A (ko) 2023-10-23 2025-04-30 케이원팜 주식회사 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
KR20250100928A (ko) 2023-12-27 2025-07-04 케이원팜 주식회사 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019974A1 (en) 1994-12-27 1996-07-04 Kanebo, Ltd. Sustained-release preparation
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
JPH10316576A (ja) * 1997-05-13 1998-12-02 Nissui Pharm Co Ltd キトサン含有錠剤
RU2205191C1 (ru) 2001-12-27 2003-05-27 Институт синтетических полимерных материалов им. Н.С. Ениколопова РАН Способ получения аморфизованного поливинилового спирта
AU2007245022A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
AU2006248109B2 (en) 2005-05-13 2012-11-15 The Regents Of The University Of California Diarylhydantoin compounds
MX340436B (es) 2008-09-12 2016-07-08 Daiichi Sankyo Healthcare Co Ltd Formulacion farmaceutica estable con descoloramiento limitado.
CA2790924C (en) 2010-02-24 2016-08-02 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
PT2688557T (pt) * 2011-03-23 2017-11-23 Ironshore Pharmaceuticals & Dev Inc Métodos e composições para o tratamento de distúrbio de défice de atenção
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
US20150239848A1 (en) 2012-09-11 2015-08-27 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
HUE057701T2 (hu) * 2012-09-11 2022-05-28 Medivation Prostate Therapeutics Llc Enzalutamid kiszerelési formái
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
JP6274641B2 (ja) 2013-09-13 2018-02-07 独立行政法人 国立印刷局 偽造防止媒体及びその作製方法
WO2015115453A1 (ja) * 2014-01-30 2015-08-06 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
JP6666254B2 (ja) * 2014-02-05 2020-03-13 レツク・フアーマシユーテイカルズ・デー・デー アンドロゲン受容体アンタゴニストの固体医薬組成物
EP3135287B1 (en) 2014-04-25 2024-11-20 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
CN107205935A (zh) * 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体
JP6403615B2 (ja) 2015-03-18 2018-10-10 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法
JP2016056208A (ja) 2016-01-15 2016-04-21 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法

Also Published As

Publication number Publication date
KR102684756B1 (ko) 2024-07-15
PT3616696T (pt) 2025-04-03
RU2019138248A3 (es) 2021-07-21
ES3018265T3 (en) 2025-05-14
CN110573153B (zh) 2023-04-04
EP3616696B1 (en) 2025-03-05
US20200146977A1 (en) 2020-05-14
JP7172997B2 (ja) 2022-11-16
MX394857B (es) 2025-03-24
CA3060366A1 (en) 2018-11-01
RU2019138248A (ru) 2021-05-28
AU2018256998B2 (en) 2023-11-09
KR20190137920A (ko) 2019-12-11
AU2018256998A1 (en) 2019-12-05
EP3616696A4 (en) 2021-01-27
US12036315B2 (en) 2024-07-16
WO2018199282A1 (ja) 2018-11-01
CN110573153A (zh) 2019-12-13
PL3616696T3 (pl) 2025-05-05
JPWO2018199282A1 (ja) 2020-03-12
EP3616696A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
MX2019012757A (es) Composicion farmaceutica para administracion oral que comprende enzalutamida.
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
BR112018010018A2 (pt) moduladores de ror-gama
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
BR112021019999A2 (pt) Formulação de comprimido vaginal
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
BR112016024510A2 (pt) ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?
TR201821115A2 (tr) Montelukast ve levoseti̇ri̇zi̇n i̇çeren farmasöti̇k bi̇leşi̇m
BR112018072583A2 (pt) composição farmacêutica de comprimido em comprimido estável
BR112022008365A2 (pt) Inibidores de cd73